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Abstract
Nocardia is an uncommon pathogen, but immunosuppression, its main risk factor, is becoming more frequent. We aimed to evaluate
changes in the annual incidence of nocardiosis and in the susceptibility profile of its aetiological agents. Demographic data were analysed
for all isolates of Nocardia forwarded to the provincial public health laboratory of Quebec, Canada during the last two decades. Popula-
tion incidence could be measured from 1997 onwards. Resistance patterns were analysed for those isolates selected for in vitro suscepti-
bility testing. Throughout Quebec, 575 incident cases were identified between 1997 and 2008. The annual incidence of Nocardia
infection/colonization increased from 0.33 (1997–1998) to 0.87 (2007–2008) per 100 000 inhabitants (p 0.001). In a small subset of
patients for whom detailed clinical information was available, 59% of isolates corresponded to genuine infections. Nocardia farcinica pre-
dominated in specimens representing invasive infections (blood, brain, lung or pleural aspirates). Isolates were often non-susceptible to
several antimicrobials, with the exception of amikacin and linezolid. Overall, 43% of 157 isolates were non-susceptible to trimethoprim–
sulphamethoxazole. In conclusion, Nocardia infection/colonization remains rare. However, from 1997–1998, a progressive increase in
incidence was noted in the province of Quebec. In regions such as ours, where a substantial proportion of invasive isolates are non-
susceptible in vitro to trimethoprim–sulphamethoxazole, the latter may no longer be the empirical treatment of choice in immuno-
suppressed and severely ill patients with nocardiosis.
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Introduction
The Gram-positive aerobic actinomycete Nocardia is an
uncommon human pathogen infecting the lungs, skin, central
nervous system (CNS) or other organs. It can present as local-
ized or disseminated infections [1–3]. Immunosuppression is
the main risk factor for nocardiosis and/or for disseminated
infection, especially those conditions that impair cell-mediated
immunity [1–3]. Chronic diseases associated with nocardiosis
include diabetes, alcoholism, cancer and alveolar proteinosis
[1–3]. Nocardia spp. are ubiquitous and are found worldwide
in soil and decaying organic plant matter [3,4]. The organism is
acquired by inhalation or direct inoculation into the skin, and
nosocomial transmission is rare [1]. Colonization or subclini-
cal infection occurs, especially within the respiratory tract of
patients with chronic obstructive pulmonary disease (COPD),
malignancy, asthma or bronchiectasis [3].
Data on the incidence of nocardiosis are sparse, as it is
generally not a reportable disease. Its incidence may be
increasing because of a growing population of immunocom-
promised patients and the enhanced diagnostic capacity of
microbiology laboratories [4–6]. Biochemical tests were inad-
equate for identification of species, especially the differentia-
tion of Nocardia asteroides sensu stricto from the species
within the N. asteroides complex (Nocardia abscessus, Nocardia
brevicatena/Nocardia paucivorans complex, Nocardia nova com-
plex, Nocardia transvalensis complex, Nocardia farcinica, and
Nocardia cyriacigeorgica) [1]. Reference laboratories now rely
on 16S rRNA gene sequencing, which is rapid, accurate and
reproducible [1,7–10]. However, molecular approaches com-
plicated the taxonomy: there are now 76 species of Nocardia,
25 of which can cause human disease [11,12]. Speciation
guides initial empirical treatment, as in vitro susceptibility
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testing is performed only in reference laboratories.
Trimethoprim–sulphamethoxazole has been classically
recommended [1–3].
We have noted in recent years a higher number of cases
of Nocardia infections, often involving trimethoprim–sulpha-
methoxazole-resistant isolates. To improve our therapeutic
strategies, we reviewed all cases of nocardiosis diagnosed in
our region since 1991, for which detailed information was
available, as well as the provincial public health laboratory
database, which contains basic demographic and clinical infor-
mation on a much larger number of isolates.
Materials and Methods
Patients seen at the Centre hospitalier universitaire de
Sherbrooke (CHUS)
The Centre hospitalier universitaire de Sherbrooke (CHUS)
is a 686-bed hospital that provides secondary care to the
304 702 inhabitants of the Estrie region in the Province of
Quebec, Canada, and tertiary care to adjacent regions as
well. Peripheral hospitals of the region usually forward their
putative Nocardia isolates, and it is likely that all patients
requiring treatment will be referred as well. Cases with a
positive culture for Nocardia between January 1991 and
December 2008 were identified from our computerized hos-
pital records. Presumptive identification of Nocardia isolates
was based on microscopic observation of branching Gram-
positive bacilli, acid-fast by the modified Kinyoun stain, from
a typical dry-chalky colony with aerial hyphae on Lowen-
stein–Jensen medium [11]. All isolates were sent to the Lab-
oratoire de sante´ publique du Que´bec (LSPQ—provincial
public health laboratory) for further confirmation and antimi-
crobial susceptibility testing. We sought to identify additional
cases from the discharge diagnoses database, based on ICM-
9 codes for nocardiosis. Permission to review these records
was obtained from the CHUS institutional review board.
We collected socio-demographic data, past medical his-
tory and clinical, diagnostic, therapeutic and microbiology
data concerning the episode of nocardiosis. A patient was
considered to be infected with a Nocardia species if he or
she presented with symptoms or signs compatible with a no-
cardial infection and no other pathogen was isolated or if
the pathogen was isolated from a sterile site. Patients were
considered to be colonized if a Nocardia species was isolated
from a non-sterile site without compatible symptoms, signs
or radiological signs, and no treatment was ordered by the
medical team.
For determination of incidence rates, numerators included
only partients living in the Estrie region. Denominators were
obtained from the Institut de la statistique du Que´bec [13].
Rates were calculated only from 1997 onwards, after the
four hospitals of Sherbrooke were merged, so it was very
unlikely that cases could have been missed by our search
methods. Annual incidences were calculated for 2-year peri-
ods to decrease random variations. To allow comparisons
with the provincial data, we present data for infection and
colonization combined.
Isolates characterized at the LSPQ
Nearly all suspected Nocardia isolates are submitted by the
Quebec hospital laboratories to the LSPQ for further char-
acterization. Its entire database of Nocardia isolates obtained
between 1988 and 2008 was reviewed. In 1994, biochemical
and chemotaxonomic tests were replaced with HPLC and
selected traditional tests [14]. From mid-2006, identification
was based solely on sequencing of the 16S rRNA gene, colo-
nial morphology and microscopic examination [1,7–11,15].
When requested by the attending physician or if the speci-
men came from a sterile site, isolates were forwarded to the
CDC for in vitro susceptibility testing by broth microdilution
[16]. Information provided by the primary laboratory (age,
sex, source of clinical specimen and, from 1997, region of
residence) is kept in the LSPQ database. To avoid any bias
from the repeated testing of colonized patients, we consid-
ered only the first isolate per patient for a given species, tak-
ing into account changes in taxonomy. A patient infected
with two different species of Nocardia was tabulated as two
events. We analysed secular changes in species and resis-
tance patterns, keeping in mind the changes in taxonomy and
identification methods.
For the determination of incidence, a patient with dual
infections (two species in one or more specimens obtained
within 1 year) and a patient with multiple isolates of the
same species over a long period of time would be counted
as a single episode occurring at the time of initial isolation.
Annual infection/colonization incidence was calculated over
2-year periods, and only from 1997 onwards, when infor-
mation on the region of residence became available for all
isolates. To detect possible biases in the referral of speci-
mens, incidence rates were calculated for the heavily popu-
lated Montreal metropolitan area (the island of Montreal
and peripheral regions; the population in 2008 was
4 129 824) and the rest of Quebec (population of
3 620 680).
Data analysis
Proportions were compared with the chi-squared test or
Fisher’s test when appropriate. Continuous variables were
compared with rank sum tests. Linear regression lines
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were fitted to determine trends in nocardiosis rates, and
the t-test was used to determine the significance of these
trends.
Results
The CHUS patients—Estrie region
We identified 32 patients with at least one isolate of Nocar-
dia processed at the CHUS. Their median age was 59 years
(interquartile range 49.5–74.5) and 56% were male. Forty-
seven per cent of the patients were immunosuppressed, and
56% had COPD. Nineteen patients (59%) had been consid-
ered by their attending physicians to be infected, and 13
were thought to be colonized (11 in respiratory secretions;
two in skin swabs). These two groups did not differ signifi-
cantly in their median age, sex distribution or past history of
COPD (data not shown). Fifty-nine per cent of the infected
patients and 31% of the colonized patients were immunosup-
pressed. N. farcinica was found in 32% of the infected
patients and 15% of the colonized patients. All of these dif-
ferences were non-significant. The only significant difference
was in the use of long-term (‡30 days) corticosteroids: 59%
among the infected patients and 15% among the colonized
patients (p 0.04).
Three infected patients died with nocardiosis as a contrib-
uting factor, but treatment had been stopped because of the
severity of their underlying conditions. Fifteen patients
received trimethoprim–sulphamethoxazole at some point in
their treatment. Eight of 11 (73%) infected patients for
whom susceptibility testing was available were infected with
an isolate resistant to trimethoprim–sulphamethoxazole. In
four cases, treatment was modified when such results
became available. In four other cases, trimethoprim–sulpha-
methoxazole was continued despite in vitro resistance, with-
out clinical failure. No recurrence was documented.
The annual incidence rates of both infected and colonized
individuals per 100 000 inhabitants for the Estrie region
increased from 0 in 1997–1998 to 0.52 in 1999–2000, 0.51
in 2001–2002, 0.17 in 2003–2004, 1.00 in 2005–2006 and
1.32 in 2007–2008 (p 0.09).
Isolates characterized at the LSPQ
Table 1 displays the characteristics of the patients whose iso-
lates (n = 718, obtained from 704 individuals) were submit-
ted to the LSPQ by hospital laboratories across Quebec
between 1988 and 2008; they are also presented in two
periods according to the taxonomy changes. The median age
of patients increased slightly. The preponderance of male
patients decreased, and the proportion of patients living out-
side the Montreal metropolitan area increased. After
improved differentiation of species, N. nova, N. cyriacigeorgica
and N. farcinica were the three most frequently identified
species. The proportion and number of isolates obtained
from sputum or bronchoscopy specimens increased over
time, whereas the proportion and number of those obtained
from lung biopsy specimens, pleural aspirates, skin specimens
and bone specimens decreased.
Table 2 shows the distribution of isolated species accord-
ing to the source of specimens, stratified between 1988 and
2003, when speciation was only moderately adequate, and
between 2004 and 2008, corresponding to the current tax-
onomy. During 1988–2003, species considered to be part of
the N. asteroides complex predominated in most types of
specimen. In skin and soft tissues, Nocardia brasiliensis and
Nocardia pseudobrasiliensis were almost as important. Within
TABLE 1. Characteristics of 718 Nocardia spp. isolates,
Quebec, 1988–2003 vs. 2004–2008
1988–2003 2004–2008
Characteristics 393 isolates 325 isolates p-value
Age (years)
Median 65.5 69 0.006
Interquartile range 52–75 57–77
Sex, N (%)
Female 131 (34) 138 (42) 0.02
Male 260 (66) 187 (58)
Residencea, N (%)
Montreal metropolitan area 152 (59) 153 (47) 0.01




219 (56) 4 (1) NR




Nocardia nova complexb 71 (18) 109 (34)
Nocardia transvalensis complexc 2 (0) 4 (1)
Nocardia farcinica 42 (11) 44 (14)
Nocardia cyriacigeorgica 3 (0) 67 (21)
Nocardia brasiliensis, Nocardia
pseudobrasiliensis
28 (7) 13 (4)
Nocardia otitidiscaviarum complex 17 (4) 4 (1)
All othersd 6 (2) 26 (8)
Not speciated 4 (1) 37 (11)
Type of specimene, N (%)
Sputum 127 (35) 135 (42) 0.01
Bronchial secretions or lavage 107 (30) 125 (39) 0.002
Lung biopsy/pleural fluid 39 (11) 13 (4) 0.004
Soft tissue or bone 60 (17) 32 (10) 0.04
Blood 9 (2) 9 (3) NS
Central nervous system 9 (2) 3 (1) NS
All othersf 12 (3) 7 (2) NS
NR, not relevant because of taxonomy changes; NS, not significant.
aIncomplete before 1997.
bN. nova (120), N. nova complex (55), Nocardia veterana (three), Nocardia elegans
(two) and Nocardia kruczakiae (one).
cN. transvalensis complex (two), N. transvalensis (two) Nocardia wallacei (two).
dNocardia arthritidis Nocardia asiatica (six each), Nocardia flavorosea (three), Nocar-
dia takedensis, Nocardia puris, Nocardia higoensis, Nocardia carnea, Nocardia vinacea,
Nocardia thailandica, Nocardia jiangxiensis, Nocardia beijingensis (one each); Nocar-
dia autotrophica (three isolates) and Nocardia orientalis (two isolates) were later
reclassified as Pseudonocardia autotrophica and Amycolatopsis orientalis, respec-
tively.
eExcluding 31 isolates for which the source was unknown.
fUrine (four), abdominal (12), eye (three), pericardium (one).
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the N. asteroides complex, and bearing in mind that in the
first interval speciation was suboptimal, N. farcinica was much
more important in specimens corresponding to an invasive
infection (CNS specimens, blood, lung biopsy specimens or
pleural aspirates) than in those that might have reflected col-
onization. The same observations were noted in 2004–2008,
but the overwhelming majority of formerly N. asteroides sp.
N. asteroides complex were by then newly named species.
N. nova complex and N. cyriacigeorgica were found mostly in
the respiratory tract.
Table 3 illustrates the prevalence of antimicrobial non-sus-
ceptibility among the most commonly isolated species in
Quebec, based on 157 susceptibility tests performed at the
CDC between 1997 and 2008. Our Nocardia isolates were
often non-susceptible to several antimicrobials, with the
exception of amikacin, with 97% susceptibility, and linezolid,
with 100% susceptibility. Overall, 43% of the isolates were
non-susceptible to trimethoprim–sulphamethoxazole, with
N. farcinica being the most resistant species (85%), followed
by N. nova.
A total of 575 incident cases were identified between
1997 and 2008. Fig. 1 shows the annual incidence of infection
and colonization from 1997–1998. The incidence increased
progressively, but more markedly outside the Montreal
metropolitan area (p 0.001). For the whole province, the
annual incidence increased 2.6-fold, from 0.33 to 0.87 per
100 000 inhabitants (p 0.001).
Discussion
Nocardia infection/colonization remained a rare event but,
from 1997–1998, we noted a progressive increase in its inci-
dence in our region and in the entire province of Quebec.
We could not discriminate true infection from colonization,
except for the CHUS patients, three-fifths of whom pre-
sented with genuine infections. Most instances of coloniza-
tion were detected in COPD patients whose sputum was
sent to the clinical laboratory for investigation. Similarities in
the specimen sources of isolates and in secular changes in
Nocardia incidence suggest that the proportion of true infec-
tions for the province was probably comparable to that for
the Estrie region.
Few authors have measured the population incidence of
nocardiosis. In Queensland, Australia, among 93 isolates
obtained from 1983 to 1988, 74 were considered to repre-
sent true infections, giving an incidence of 0.4 per 100 000
inhabitants [17,18]. In a sub-area of Madrid, Spain, only six
of 43 isolates were considered to represent colonization,
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for 1995–1998 and 0.55 per 100 000 inhabitants for
2003–2006 [19]. Our estimate, based on 575 isolates, was
much more robust, but gave incidence rates similar to
those reported in Spain. On the assumption that, through-
out Quebec, the proportion of isolates corresponding to
genuine infections was the same as in the Estrie region, the
incidence of Nocardia infection for the entire province can
be estimated as 0.51 per 100 000 in 2007–2008. To our
knowledge, this is the first study that is sufficiently pow-
ered to document an increasing incidence of Nocardia infec-
tion/colonization.
This increasing incidence throughout Quebec may be
attributable to several factors. First, there might have been a
more systematic referral of isolates to the LSPQ during
recent years, especially from laboratories outside the Mon-
treal metropolitan area, for which the increase in incidence
was more marked. Second, hospital laboratories might have
improved their proficiency in recovering and recognizing
presumptive Nocardia spp. Automated systems utilizing
enriched liquid media, first implemented only in larger labo-
ratories for faster detection of mycobacteria, have been
more widely used during the last decade. They have poten-
tially improved the isolation rate for Nocardia isolates, as for
the non-tuberculous mycobacteria. Third, nocardiosis is
more common among older persons, and the ageing of our
population might have played a role. Fourth, higher risks of
nocardiosis have been reported among immunocompromised
patients, whose numbers are increasing in Quebec, as else-
where [4,5,17,20,21].
Another important finding of our study is the frequency
of isolation of N. farcinica from specimens reflecting invasive
disease, such as brain or lung biopsy specimens, pleural aspi-
rates and blood. Its underestimated contribution in the ear-
lier period, when speciation was less accurate, did not allow
us to evaluate whether the distribution truly changed over
time. In Belgium, where current molecular methods were
used for 86 Nocardia isolates, N. farcinica was the most com-
mon species (44%), followed by N. nova (22%) and N. cyriaci-
georgica (15%) [22]. N. farcinica was isolated mainly in blood
and brain biopsy specimens, as in Europe and the USA
[2,22,23]. Although many of the Quebec isolates of N. cyriaci-
georgica were of uncertain clinical significance, we docu-
mented eight cases in which the species was clearly an
invasive pathogen [24].
Trimethoprim–sulphamethoxazole is generally recom-
mended for the empirical treatment of nocardiosis [1–3,
25,26]. Given the preponderance of invasive N. farcinica and
the frequent non-susceptibility of our isolates to trimetho-
prim–sulphamethoxazole, this may no longer be appropriate

































Trimethoprim–sulphamethoxazole 5 (17) 0 19 (61) 29d (85) 4 (19) 4 (31) 7 (33) 68 (43)
Amikacin 0 0 0 2 (6) 0 0 3 (14) 5e (3)
Imipenem 9 (30) 4 (57) 2 (6) 14 (41) 11 (52) 11 (85) 12 (57) 63 (40)
Ceftriaxone 2 (7) 0 15 (48) 12/33 (94) 1 (5) 11 (85) 8 (38) 68/156 (44)
Amoxycillin–clavulanate 16 (53) 1 (14) 29 (94) 10 (29) 20 (95) 2 (15) 7 (33) 94 (60)
Minocycline 10 (33) 0 13 (42) 25 (74) 18 (86) 10 (77) 4 (19) 80f (51)
Ciprofloxacin 30 (100) 7 (100) 31 (100) 22 (65) 20 (95) 12 (92) 16 (76) 138 (88)
Clarithromycin 14/14 (100) 7 (100) 0 28/28 (100) 21 (100) 9/11 (82) 16 (76) 95/126 (75)
Linezolid 0/14 0 0 0/28 0 0 0 0/126 (0)
aBreakpoints for resistance are those of the CLSI [16].
bThe majority of these isolates are not N. asteroides sensu stricto but species of the N. asteroides complex when speciation was inadequate.
cNocardia spp. (six), Nocardia otitidiscaviarum (four), Nocardia arthritidis (two), Nocardia puris (two), Nocardia transvalensis complex (two), Nocardia asiatica (one), Nocardia carnea
(one), Nocardia higoensis (one), Nocardia pseudobrasiliensis (one), Nocardia vinacea (one).
dAmong the 29 N. farcinica isolates resistant to trimethoprim–sulphamethoxazole, five had MIC 4/76, five had MIC 8/152, and the other ten had MIC >8/152 mg/L.
eBoth N. farcinica isolates had MIC 16 mg/L.
fOnly seven isolates were resistant (MIC 8 mg/L), and the others were intermediate.
FIG. 1. Trends in the annual incidence of Nocardia infection/coloni-
zation per 100 000 inhabitants, Quebec, 1997–2008.
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in Quebec. The susceptibility of N. farcinica to trimethoprim–
sulphamethoxazole varies geographically, but the comparison
is confounded by the use of different methodologies [23,25–
29]. In regions such as ours, where non-susceptibility to tri-
methoprim–sulphamethoxazole is frequent, clinicians may
want to consider other empirical treatments for patients for
whom Nocardia spp. are isolated from CNS, blood, lung
biopsy specimens or pleural aspirate, as well as for immuno-
suppressed patients. Even though in vitro antimicrobial non-
susceptibility has not clearly been associated with clinical fail-
ures, treatment with a drug considered to be active on the
basis of CLSI breakpoints would seem to be advisable. For
non-CNS infections, empirical therapy with amikacin and/or
linezolid might be considered. For CNS nocardiosis, linezolid,
which crosses the blood–brain barrier and has an excellent
bioavailability, is an attractive alternative. Although clinical
experience is limited, linezolid seems, so far, to be quite
effective [30,31].
In conclusion, although nocardiosis remains rare, its infec-
tion/colonization incidence more than doubled in Quebec
from 1997 to 2008. N. farcinica, which was frequently recov-
ered in CNS, blood, lung or pleural specimens, was often
non-susceptible to trimethoprim–sulphamethoxazole. In
regions such as ours, where non-susceptibility to trimetho-
prim–sulphamethoxazole is frequent, other drugs should be
considered for the empirical treatment of nocardiosis, espe-
cially in severely ill and/or immunosuppressed patients.
Future studies should attempt to correlate in vitro susceptibil-
ity with response to treatment.
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